Market Research Logo

Genethon SA - Product Pipeline Review - 2016

Genethon SA - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Genethon SA - Product Pipeline Review - 2016’, provides an overview of the Genethon SA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genethon SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Genethon SA
  • The report provides overview of Genethon SA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genethon SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genethon SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Genethon SA’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genethon SA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genethon SA’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Genethon SA Snapshot
Genethon SA Overview
Key Facts
Genethon SA - Research and Development Overview
Key Therapeutic Areas
Genethon SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Genethon SA - Pipeline Products Glance
Genethon SA - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Genethon SA - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Genethon SA - Drug Profiles
Cell Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPK-850 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1XCGD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Sickle Cell Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Gamma-Sarcoglycan for Gamma Sarcoglycanopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SGCA for Alpha-Sarcoglycanopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate UGT1A1 for Crigler-Najjar Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate WASP for Wiskott-Aldrich Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Genethon SA - Pipeline Analysis
Genethon SA - Pipeline Products by Target
Genethon SA - Pipeline Products by Route of Administration
Genethon SA - Pipeline Products by Molecule Type
Genethon SA - Pipeline Products by Mechanism of Action
Genethon SA - Dormant Projects
Genethon SA - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Genethon SA, Key Facts
Genethon SA - Pipeline by Indication, 2016
Genethon SA - Pipeline by Stage of Development, 2016
Genethon SA - Monotherapy Products in Pipeline, 2016
Genethon SA - Partnered Products in Pipeline, 2016
Genethon SA - Partnered Products/ Combination Treatment Modalities, 2016
Genethon SA - Phase II, 2016
Genethon SA - Preclinical, 2016
Genethon SA - Discovery, 2016
Genethon SA - Pipeline by Target, 2016
Genethon SA - Pipeline by Route of Administration, 2016
Genethon SA - Pipeline by Molecule Type, 2016
Genethon SA - Pipeline Products by Mechanism of Action, 2016
Genethon SA - Dormant Developmental Projects,2016
List of Figures
Genethon SA - Pipeline by Top 10 Indication, 2016
Genethon SA - Pipeline by Stage of Development, 2016
Genethon SA - Monotherapy Products in Pipeline, 2016
Genethon SA - Partnered Products in Pipeline, 2016
Genethon SA - Pipeline by Top 10 Target, 2016
Genethon SA - Pipeline by Route of Administration, 2016
Genethon SA - Pipeline by Molecule Type, 2016
Genethon SA - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report